{
    "clinical_study": {
        "@rank": "28526", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm study will evaluate the safety, efficacy, and tolerability of\n      subcutaneously administered RoActemra/Actemra (tocilizumab) in monotherapy or in combination\n      with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs (DMARDs)\n      in patients with active rheumatoid arthritis who are na\u00efve to RoActemra/Actemra. Patients\n      will receive RoActemra/Actemra 162 mg subcutaneously weekly for 24 weeks."
        }, 
        "brief_title": "A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Active rheumatoid arthritis (RA) according to the revised (1987) ACR criteria or\n             EULAR/ACR (2010) criteria\n\n          -  Moderate to severe RA with a DAS28-ESR > 3.2\n\n          -  Inadequate response and/or intolerance to MTX or other non-biologic DMARDs and/or\n             where MTX or other non-biologic DMARDs are inappropriate\n\n          -  Oral corticosteroids (</= 10 mg/day prednisolone or equivalent) and non-steroidal\n             anti-inflammatory drugs (NSAIDs) are permitted if on stable dose regimen for >/= 4\n             weeks prior to baseline\n\n          -  Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline\n\n          -  Receiving treatment on an outpatient basis, not including RoActemra/Actemra\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential must agree to use reliable means of contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned\n             major surgery within 6 months following baseline\n\n          -  Rheumatic autoimmune disease other than RA\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status in\n             Rheumatoid Arthritis\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of\n             16\n\n          -  Prior history of or current inflammatory joint disease other than RA\n\n          -  Exposure to RoActemra/Actemra or any other biologic DMARDs at any time prior to\n             baseline\n\n          -  Treatment with any investigational agent within 4 weeks (or 5 half-lives of the\n             investigational drug, whichever is longer) of screening\n\n          -  Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline\n\n          -  History of severe allergic or anaphylactic reactions to human, humanized or murine\n             monoclonal antibodies\n\n          -  Evidence of serious concomitant disease or disorder\n\n          -  Known active current or history of recurrent infection\n\n          -  Any major episode of infection requiring hospitalization or treatment with IV\n             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of\n             screening\n\n          -  Active TB requiring treatment within the previous 3 years\n\n          -  Positive for hepatitis B or hepatitis C\n\n          -  Primary or secondary immunodeficiency (history of or currently active)\n\n          -  Pregnant or lactating women\n\n          -  Neuropathies or other conditions that might interfere with pain evaluation\n\n          -  Inadequate hematologic, renal or liver function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046616", 
            "org_study_id": "ML28691"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "162 mg administered subcutaneously weekly", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alborg", 
                        "country": "Denmark", 
                        "zip": "9000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glostrup", 
                        "country": "Denmark", 
                        "zip": "2600"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hellerup", 
                        "country": "Denmark", 
                        "zip": "2900"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8ge", 
                        "country": "Denmark", 
                        "zip": "4600"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark", 
                        "zip": "5000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00290"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyvink\u00e4\u00e4", 
                        "country": "Finland", 
                        "zip": "05800"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Joensuu", 
                        "country": "Finland", 
                        "zip": "80210"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jyv\u00e4skyl\u00e4", 
                        "country": "Finland", 
                        "zip": "40620"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lappeenranta", 
                        "country": "Finland", 
                        "zip": "53130"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland", 
                        "zip": "90220"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riihim\u00e4ki", 
                        "country": "Finland", 
                        "zip": "11101"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway", 
                        "zip": "5053"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Drammen", 
                        "country": "Norway", 
                        "zip": "3004"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0370"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linkoeping", 
                        "country": "Sweden", 
                        "zip": "58185"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "221 85"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malmo", 
                        "country": "Sweden", 
                        "zip": "205 02"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Simrishamn", 
                        "country": "Sweden", 
                        "zip": "272 81"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "171 76"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden", 
                        "zip": "75185"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "V\u00e4ster\u00e5s", 
                        "country": "Sweden", 
                        "zip": "72189"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Finland", 
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-arm, Open-label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will be Measured by Ultrasound", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28691 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Sundhedsstyrelsen (National Board of Health)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Clinical Disease Activity Index (CDAI)", 
            "safety_issue": "No", 
            "time_frame": "From baseline to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046616"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) score", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change in American College of Rheumatology (ACR) response scores", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change in European League Against Rheumatism (EULAR) response criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change in total tender/swollen joint count (TJC/SJC)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 32"
            }, 
            {
                "measure": "Incidence of anti-tocilizumab antibodies", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 32"
            }, 
            {
                "measure": "Patient reported quality of life", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}